- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04916457
The Role of Skin Microecology in Diabetic Skin Lesions
Explore the Role of Skin Microecology in Diabetic Skin Lesions Based on Multi-omics Data Analysis
Descripción general del estudio
Estado
Condiciones
Descripción detallada
The study intends to explore the mechanism of diabetic skin micro-ecology in diabetic skin diseases, and find new ways of early screening and prevention for diabetic foot.
This study is a prospective observational study. Adult participants were divided into the following 5 groups (n=200, 40 in each group): control group, very low-risk group, low-risk group, moderate-risk group, and high-risk group. Sterile rayon tipped swabs were pre-moistened with a sterile solution containing 0.15 M NaCl and 0.1% Tween 20. All swabs samples were collected from the intact skin at plantar anterior. And the skin cotton swab was subjected to 16s rDNA high-throughput sequencing, metagenomic sequencing methods, etc. Based on the result, the investigators will analyse the change of the cutaneous microbiome in DM as the disease condition progresses.
The skin tissues of the control group and observation group who met the inclusion criteria were also collected during surgical operations, and pathological and immunohistochemistry tests were performed respectively to analyze the pathological changes of diabetic skin tissues in different disease progressions.
According to the results of multi-omics analysis, the research team screen for the specific flora. Then sort out and culture specific strains, and establish mouse model of microbiota transplantation in order to explore the effects of regulating skin microecology on diabetic skin lesions through different treatment methods such as hypoglycemic drugs and probiotic emulsions.
Researchers will conduct telephone follow-ups of diabetic patients, collect data, and statistically analyze the impact of changes in the skin microecology of diabetic patients on the occurrence of diabetic foot ulcers.
Tipo de estudio
Inscripción (Anticipado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Xiaoyan Tan
- Número de teléfono: 02062786842
- Correo electrónico: nfyykyc@163.com
Copia de seguridad de contactos de estudio
- Nombre: Shili Zhang
- Número de teléfono: +86-17817182600
- Correo electrónico: sallyz11@163.com
Ubicaciones de estudio
-
-
Guangdong
-
Guangzhou, Guangdong, Porcelana, 518000
- Reclutamiento
- Nanfang Hospital
-
Contacto:
- Xiaoyan Tan
- Número de teléfono: 02061641036
- Correo electrónico: nfyykyc@163.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
1. Surface skin cotton swab collection
(1) Observation group: In the endocrinology department of Nanfang hospital, the patient were diagnosed with type 2 diabetes to the WHO 1999 diagnostic criteria for diabetes.
(2) Control group:
- Control subjects that was ruled out diabetes according to the WHO 1999 diagnostic criteria for euglycemia.
- Age ≥18 years, the patient and (or) his family members know and agree to participate in this study.
2. Skin tissue collection
(1) Observation group:
- The patient was diagnosed with type 2 diabetes in the Endocrinology Department, Burns Department, Traumatology Orthopedics, Plastic Surgery in Nanfang hospital.
- Patients who need surgical operations such as debridement and amputation below the knee joint due to various reasons such as diabetic foot osteomyelitis, fractures, car accidents and so on.
(2) Control group:
- The patient without type 2 diabetes in the Endocrinology Department, Burns Department, Traumatology Orthopedics, Plastic Surgery in Nanfang hospital.
- Patients who need surgical operations such as debridement and amputation below the knee joint due to various reasons such as post-traumatic foot osteomyelitis, fractures, car accidents and so on.
- Age ≥18 years, the patient and (or) his family members know and agree to participate in this study.
Exclusion Criteria:
The patients Including other skin diseases, using medically prescribed soap for bathing, using cosmetics on the feet, suffering from severe liver and kidney disease, immune system disease, HIV infection, malignant tumors, or using immunosuppressive drugs within the first four weeks. The patient or (and) their family members refused to participate in this study.
The researchers judged that they are not suitable to participate in this research.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
---|
group ND
control group without DM non-intervention
|
group VD
very low-risk group: diabetic patient with no loss of protective sensation(LOPS) and no peripheral artery disease(PAD). non-intervention |
group LD
low-risk group: diabetic patient with LOPS or PAD non-intervention
|
group MD
moderate-risk group: diabetic patient with LOPS + PAD non-intervention
|
group HD
high-risk group: diabetic patient with LOPS or PAD, and one or more of the following:
non-intervention |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
omics analysis of skin microbiome
Periodo de tiempo: from September 2020 to July 2021
|
Compared with non-diabetic patients, the differences in skin microbiome of diabetic patients with different disease progression.
|
from September 2020 to July 2021
|
change of skin pathology in DM
Periodo de tiempo: From August 2021 to July 2024
|
The pathological changes of the skin tissues of diabetic patients with different disease progression.
|
From August 2021 to July 2024
|
The incidence of developing into diabetic foot among the groups
Periodo de tiempo: From August 2023 to July 2025
|
Follow-up for 2 years to assess the impact of changes in the skin microecology of diabetic patients on the occurrence of diabetic foot ulcers
|
From August 2023 to July 2025
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- NFEC-2020-306
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .